Video

Taking a Closer Look at PCSK9 Part 2

Author(s):

If the new class of drugs are as effective as they appear to be in early studies, it could have a drastic affect on how patients with cardiac issues are treated in the future.

If the new class of drugs are as effective as they appear to be in early studies, it could have a drastic affect on how patients with cardiac issues are treated in the future.

Jennifer Robinson, MD, MPH, from the University of Iowa discussed how the landscape could change with these new drugs and what it could mean to overall patient care at the American College of Cardiology's Annual Scientific Sessions and Expo in San Diego.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.